RU2770050C2 - Способ лечения с применением традипитанта - Google Patents
Способ лечения с применением традипитанта Download PDFInfo
- Publication number
- RU2770050C2 RU2770050C2 RU2017134443A RU2017134443A RU2770050C2 RU 2770050 C2 RU2770050 C2 RU 2770050C2 RU 2017134443 A RU2017134443 A RU 2017134443A RU 2017134443 A RU2017134443 A RU 2017134443A RU 2770050 C2 RU2770050 C2 RU 2770050C2
- Authority
- RU
- Russia
- Prior art keywords
- tradipitant
- day
- atopic dermatitis
- dose
- plasma concentration
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Eye Examination Apparatus (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128472P | 2015-03-04 | 2015-03-04 | |
| US62/128,472 | 2015-03-04 | ||
| US201562232644P | 2015-09-25 | 2015-09-25 | |
| US62/232,644 | 2015-09-25 | ||
| PCT/US2016/021015 WO2016141341A1 (en) | 2015-03-04 | 2016-03-04 | Method of treatment with tradipitant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2022102184A Division RU2810253C2 (ru) | 2015-03-04 | 2016-03-04 | Способ лечения с применением традипитанта |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017134443A RU2017134443A (ru) | 2019-04-04 |
| RU2017134443A3 RU2017134443A3 (cg-RX-API-DMAC7.html) | 2019-09-05 |
| RU2770050C2 true RU2770050C2 (ru) | 2022-04-14 |
Family
ID=55629110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017134443A RU2770050C2 (ru) | 2015-03-04 | 2016-03-04 | Способ лечения с применением традипитанта |
Country Status (19)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3265087T3 (da) * | 2015-03-04 | 2020-10-19 | Vanda Pharmaceuticals Inc | Fremgangsmåde til behandling med tradipitant |
| CA3073998A1 (en) * | 2017-09-13 | 2019-03-21 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| PT3710000T (pt) * | 2017-11-17 | 2025-05-29 | Vanda Pharmaceuticals Inc | Tradipitant para utilização no tratamento de gastroparesia |
| WO2019236852A1 (en) | 2018-06-08 | 2019-12-12 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| CN111918701B (zh) * | 2018-09-28 | 2024-08-02 | 万达制药公司 | 曲地匹坦在晕动病中的用途 |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| US20220096449A1 (en) * | 2018-12-03 | 2022-03-31 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2020132513A1 (en) | 2018-12-21 | 2020-06-25 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| IL295327A (en) | 2020-02-25 | 2022-10-01 | Vanda Pharmaceuticals Inc | Improved treatment of atopic dermatitis with tradipitant |
| JP7791832B2 (ja) * | 2020-03-26 | 2025-12-24 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる下気道感染症の治療 |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| KR20250123807A (ko) | 2022-12-21 | 2025-08-18 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 치료 방법 |
| EP4599831A1 (en) | 2024-02-09 | 2025-08-13 | Vanda Pharmaceuticals Inc. | Treatment of gastroparesis with tradipitant |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003091226A1 (en) * | 2002-04-26 | 2003-11-06 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9305718D0 (en) * | 1993-03-19 | 1993-05-05 | Glaxo Group Ltd | Medicaments |
| TW263498B (cg-RX-API-DMAC7.html) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| GB9513972D0 (en) | 1995-07-08 | 1995-09-06 | Merck Sharp & Dohme | Pharmaceutical compositions |
| SI1035115T1 (en) | 1999-02-24 | 2005-02-28 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
| WO2003091227A1 (en) * | 2002-04-26 | 2003-11-06 | Eli Lilly And Company | Tachykinin receptor antagonists |
| JP2004250329A (ja) | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| ES2340772T3 (es) * | 2003-10-24 | 2010-06-09 | Eli Lilly And Company | Nuevas formas cristalinas (2-(1-(3,5-bis-trifluorometilbencil)-5-piridin-4-il-1h-(1,2,3)triazol-4-il)-piridin-3-il)-(2-clorofenil)-metadona. |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| DE102005006217B4 (de) | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| WO2007096782A2 (en) | 2006-02-22 | 2007-08-30 | Valorisation Recherche Hscm, Limited Partnership | Compositions for disorders associated wtth metachromatic cell activation |
| EP2121610B1 (en) * | 2006-12-20 | 2014-04-02 | Eli Lilly & Company | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| MX336071B (es) | 2009-08-14 | 2016-01-06 | Opko Health Inc | Formulaciones intravenosas de antagonistas de neurocinina 1. |
| RS55206B1 (sr) | 2009-11-18 | 2017-01-31 | Helsinn Healthcare Sa | Kompozicije za lečenje centralno posredovane mučnine i povraćanja |
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| EP2931253A1 (en) | 2012-12-13 | 2015-10-21 | Heron Therapeutics, Inc. | Pharmaceutical composition comprising antiemetic compounds and polyorthoester |
| JP6644328B2 (ja) | 2013-02-28 | 2020-02-12 | ロート製薬株式会社 | アトピー性疾患の発症又は重症化リスクの評価法 |
| CN105473138A (zh) * | 2013-06-24 | 2016-04-06 | 虎猫制药公司 | Nk-1受体拮抗剂司洛匹坦在瘙痒中的用途 |
| US8906951B1 (en) * | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| DK3265087T3 (da) * | 2015-03-04 | 2020-10-19 | Vanda Pharmaceuticals Inc | Fremgangsmåde til behandling med tradipitant |
| WO2016195723A1 (en) | 2015-06-03 | 2016-12-08 | Beller Pharmaceuticals LLC | Methods of treatment for conditions mediated by substance p |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| SI3383363T1 (sl) | 2015-11-30 | 2021-03-31 | Anacor Pharmaceuticals, Inc. | Topične farmacevtske formulacije za zdravljenje vnetnih bolezenskih stanj |
| CN108712913B (zh) | 2015-12-22 | 2022-06-24 | 武田药品工业株式会社 | 内体g蛋白-偶联的受体的三部分调节剂 |
| CA3073998A1 (en) * | 2017-09-13 | 2019-03-21 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| PT3710000T (pt) * | 2017-11-17 | 2025-05-29 | Vanda Pharmaceuticals Inc | Tradipitant para utilização no tratamento de gastroparesia |
| WO2019236852A1 (en) * | 2018-06-08 | 2019-12-12 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| CN111918701B (zh) * | 2018-09-28 | 2024-08-02 | 万达制药公司 | 曲地匹坦在晕动病中的用途 |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| US20220096449A1 (en) * | 2018-12-03 | 2022-03-31 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
-
2016
- 2016-03-04 DK DK16711931.2T patent/DK3265087T3/da active
- 2016-03-04 AU AU2016226006A patent/AU2016226006B2/en active Active
- 2016-03-04 WO PCT/US2016/021015 patent/WO2016141341A1/en not_active Ceased
- 2016-03-04 CA CA2978736A patent/CA2978736C/en active Active
- 2016-03-04 US US15/553,394 patent/US10463655B2/en active Active
- 2016-03-04 EP EP16711931.2A patent/EP3265087B1/en active Active
- 2016-03-04 PT PT167119312T patent/PT3265087T/pt unknown
- 2016-03-04 RU RU2017134443A patent/RU2770050C2/ru active
- 2016-03-04 CN CN202110527432.8A patent/CN113262221A/zh active Pending
- 2016-03-04 ES ES16711931T patent/ES2824552T3/es active Active
- 2016-03-04 EP EP20180523.1A patent/EP3730140A1/en active Pending
- 2016-03-04 HR HRP20201627TT patent/HRP20201627T1/hr unknown
- 2016-03-04 BR BR112017018620-9A patent/BR112017018620A2/pt not_active Application Discontinuation
- 2016-03-04 CN CN201680013797.6A patent/CN107427502B/zh active Active
- 2016-03-04 JP JP2017546704A patent/JP6891385B2/ja active Active
- 2016-03-04 CA CA3213864A patent/CA3213864A1/en active Pending
- 2016-03-04 KR KR1020237043041A patent/KR102860817B1/ko active Active
- 2016-03-04 HU HUE16711931A patent/HUE050944T2/hu unknown
- 2016-03-04 KR KR1020257030197A patent/KR20250136946A/ko active Pending
- 2016-03-04 MX MX2017011279A patent/MX385788B/es unknown
- 2016-03-04 KR KR1020177026588A patent/KR20170122777A/ko not_active Ceased
-
2017
- 2017-08-24 IL IL254142A patent/IL254142B/en unknown
- 2017-09-04 CL CL2017002238A patent/CL2017002238A1/es unknown
- 2017-09-04 MX MX2021010460A patent/MX2021010460A/es unknown
- 2017-09-06 ZA ZA2017/06059A patent/ZA201706059B/en unknown
-
2019
- 2019-06-04 US US16/430,516 patent/US20190290626A1/en not_active Abandoned
- 2019-06-04 US US16/430,514 patent/US10772880B2/en active Active
-
2020
- 2020-07-31 US US16/944,596 patent/US11324735B2/en active Active
-
2021
- 2021-01-28 JP JP2021012356A patent/JP2021073258A/ja active Pending
- 2021-05-10 AU AU2021202956A patent/AU2021202956B2/en active Active
-
2022
- 2022-04-06 US US17/714,998 patent/US12318375B2/en active Active
-
2023
- 2023-01-18 JP JP2023006082A patent/JP2023052486A/ja active Pending
- 2023-09-21 AU AU2023233141A patent/AU2023233141B2/en active Active
-
2024
- 2024-04-09 JP JP2024062811A patent/JP2024074963A/ja not_active Withdrawn
-
2025
- 2025-03-12 US US19/078,214 patent/US20250205213A1/en active Pending
- 2025-08-04 AU AU2025210905A patent/AU2025210905A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003091226A1 (en) * | 2002-04-26 | 2003-11-06 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
Non-Patent Citations (3)
| Title |
|---|
| D. SANTINI MD et al., Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study, The Lancet Oncology Volume 13, Issue 10, October 2012, Pages 1020-1024, PMID: 22995650. * |
| TROWER MK et al., Neurokinin‐1 receptor antagonist orvepitant is an effective inhibitor of itch‐associated response in a Mongolian gerbil model of scratching behaviourVolume23, Issue11, November 2014, c. 858-860, PMID: 25078633. * |
| TROWER MK et al., Neurokinin‐1 receptor antagonist orvepitant is an effective inhibitor of itch‐associated response in a Mongolian gerbil model of scratching behaviourVolume23, Issue11, November 2014, c. 858-860, PMID: 25078633. D. SANTINI MD et al., Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study, The Lancet Oncology Volume 13, Issue 10, October 2012, Pages 1020-1024, PMID: 22995650. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2770050C2 (ru) | Способ лечения с применением традипитанта | |
| AU2024227357A1 (en) | Ganaxolone For Use In Treating Genetic Epileptic Disorders | |
| AU2017315781B2 (en) | Use of pridopidine for treating dystonias | |
| KR20090034810A (ko) | 멜라토닌 효능제 치료 | |
| JP2016074728A (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| EA028060B1 (ru) | Комбинированная терапия бокового амиотрофического склероза | |
| RU2810253C2 (ru) | Способ лечения с применением традипитанта | |
| HK1248552B (en) | Method of treatment with tradipitant | |
| CN104906501A (zh) | 治疗银屑病的中药组分组合物 | |
| WO2024211216A1 (en) | Cilnidipine and a p-glycoprotein inhibitor for treating pain |